AI in Regulatory Affairs and CMC: From Tools to Submission-Ready Governance

Regulatory affairs and CMC (chemistry, manufacturing, and controls) teams produce the documents that decide whether a product reaches patients: the modules of an IND, NDA, or BLA, the responses to agency questions, the labeling, the variations and supplements that keep a marketed product compliant. The work is text-heavy, deadline-driven, and unforgiving of error, which is exactly the kind of work people now point AI at. Drafting a clinical overview, summarizing a 300-page study report, assembling a submission, scanning agency databases for relevant precedent: all of it has a plausible AI angle.

The promise is real, and so is the exposure. A regulatory submission is a legal representation to a health authority. A labeling change is a patient-safety document. If AI introduces an error into that content and no one catches it, the consequence is not a slow internal process, it is a misstatement to a regulator or a wrong instruction to a prescriber. This article covers where AI is genuinely useful across regulatory affairs and CMC, and, more importantly, the governance that has to sit around it so the output is accurate, traceable, and submission-ready. It is written so that after reading it you could scope an AI-assisted regulatory workflow, defend it in an inspection or a sponsor audit, and answer the questions an interviewer will ask.

This sits on top of the general work of validating AI-enabled GxP systems and the AI risk assessment for GxP method. Read those for the validation and risk mechanics; this article is about the regulatory and CMC application and the content governance specific to it.

Why Regulatory Content Is a Special Case

Most discussion of AI in GxP focuses on manufacturing and quality systems, where the AI drives or screens an operational decision. Regulatory content is different in a way that changes the governance.

The output is a representation to an authority. A submission section, a response to a deficiency letter, a labeling statement, these are not internal work products. They are the formal position of the company, signed and filed. In the US, false statements in a submission carry consequences under the Federal Food, Drug, and Cosmetic Act and, in serious cases, under statutes governing false statements to the government. The point is not to frighten anyone off using AI, it is to set the accuracy bar correctly: the standard for AI-assisted regulatory content is the same standard as for any submitted content, which is that every factual claim must be true, supported, and traceable to its source.

The content is dense with specifics that AI gets wrong in characteristic ways. Batch numbers, specification limits, stability data points, study identifiers, regulatory citations, dates. A generative model will produce fluent text around these, and it will sometimes get the specific number wrong while the surrounding prose reads perfectly. A confident, well-written misstatement of a specification limit is more dangerous than an obvious gap, because it does not announce itself.

The work is governed by data integrity expectations end to end. A submission claim traces back to a source record, a study report, a batch record, an analytical result. That data integrity foundation does not relax because an AI helped write the prose. If anything it tightens, because you now have an extra transformation step, from source data to AI-generated text, that has to preserve the meaning of the source.

So the governing principle for this whole area: AI can assist the production of regulatory content, but the accountability, the accuracy, and the traceability of that content remain exactly where they were before AI, with named humans and a documented record.

The Regulatory Direction of Travel

Two developments frame AI-assisted regulatory and CMC work, and both are worth knowing even though neither settles the question on its own.

On the US side, the FDA published a draft guidance in January 2025, “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.” It targets AI models whose output supports a regulatory decision about a product’s safety, effectiveness, or quality across the nonclinical, clinical, post-marketing, and manufacturing phases, and it proposes a seven-step, risk-based credibility assessment framework: define the question of interest, define the context of use, assess the model risk, then plan, execute, and document the credibility evidence in proportion to that risk. It is a draft, so read it for method rather than as a binding requirement, and confirm its status before relying on it. The framework maps closely onto the classify-then-size approach in this article: decide what the AI output drives and how much rides on it, then scale the evidence to match. Note the scope, though. The FDA draft is about AI models that generate data or information supporting a regulatory decision, which is narrower than the writing and assembly assist this article centers on. For a model that drafts prose a human then verifies, the full credibility-assessment machinery is heavier than the use needs; for a model whose numeric output feeds a submission claim directly, it is exactly the right lens.

On the EU side, the draft Annex 22 on artificial intelligence (published for consultation on 7 July 2025 alongside the draft Annex 11 revision, consultation closed 7 October 2025, final expected around 2026) speaks directly to generative AI, which is what most regulatory drafting uses. As drafted, it limits dynamic and generative models to non-critical uses with documented human oversight, and reserves critical GMP applications for static, deterministic models. Regulatory content generation is a generative-AI use, so the draft’s direction is consistent with the stance this article takes throughout: the AI assists, a qualified human authors and owns the output, and the human oversight is real rather than nominal. Neither the FDA draft nor Annex 22 is in force. Treat both as direction of travel, keep building to the current expectations of 21 CFR Part 11 and Annex 11 and ICH Q9(R1) quality risk management, and confirm the published text before you cite either.

Where AI Is Actually Useful

It helps to be concrete about the use cases before talking about controls, because the right control depends on what the AI is doing. Four families cover most of the real applications.

Document drafting and summarization

The largest practical use. Regulatory and medical writing involves generating long structured documents and condensing long source documents into shorter ones.

• Drafting first-pass sections of common technical document modules from structured source data: a quality overall summary section from CMC data, a nonclinical written summary from study reports, sections of a clinical overview from trial results.
• Summarizing long source documents: condensing a full clinical study report into the elements that feed a summary, pulling the relevant points out of a stability report.
• Reformatting and harmonizing: bringing terminology, units, and phrasing into line across a document set written by different authors.
• Drafting responses to agency questions, where the model assembles a first draft from the existing dossier and the question text.

The honest framing: AI produces a draft, a starting point that a qualified writer then verifies, corrects, and owns. It does not produce a finished section. The value is in cutting the blank-page time and the mechanical reformatting, not in replacing the writer’s judgment or accountability. See technical writing for GxP for the writing discipline the human still has to apply.

Submission assembly and publishing

The electronic Common Technical Document (eCTD) is a structured, hyperlinked, granular submission format with strict technical rules. AI can assist the mechanical parts:

• Checking documents against publishing requirements (hyperlink integrity, bookmarks, format conformance, granularity) before a submission is compiled.
• Suggesting where a document belongs in the eCTD structure based on its content.
• Drafting cover letters and administrative forms from structured metadata.
• Flagging inconsistencies across documents, a specification value that differs between two sections, a study referenced but not included.

The cross-document consistency check is genuinely valuable because it is the kind of tedious, error-prone work humans do badly across a large dossier. But the model flags candidates, it does not silently fix them. For the structure it is checking against, see eCTD submission architecture.

Regulatory intelligence

Scanning the external regulatory environment for information that affects the program.

• Searching and summarizing public agency databases: approved labels, guidance documents, warning letters, advisory committee materials, public assessment reports.
• Monitoring for new or revised guidance relevant to a product or modality.
• Summarizing precedent: how similar products were reviewed, what deficiencies recurred, what commitments were made.
• Comparative analysis across regions, where the same product faces different requirements.

This is a strong fit because the inputs are public and the output is internal intelligence rather than a submitted document, which lowers the stakes of an individual error while still requiring that conclusions be checked before they drive a strategy decision. The regulatory intelligence and 483 trends article covers the discipline; AI changes the speed, not the need to verify.

Labeling and change management

Labeling is the highest-stakes regulatory content because it directly instructs prescribers and patients.

• Comparing label versions to surface every change between two revisions (redline assistance).
• Checking a proposed label against the approved core data sheet or against regional requirements.
• Drafting change-control documentation for a variation or supplement.
• Cross-referencing a labeling claim back to the supporting data.

AI assists the comparison and the drafting, but a labeling change is reviewed and approved through controlled change control, with qualified human sign-off, every time. There is no version of this where the model’s output goes to a label unchecked.

The Governance Framework

The rest of this article is the part that matters for an audit or an interview: how you wrap these use cases so the output is defensible. The framework has seven elements. Each gets the WHY, the WHAT, the HOW, acceptance criteria, common mistakes, and where relevant a worked detail.

1. Classify the use and set the accountability

WHY. Every downstream control is sized by what the AI is doing and how its output is used. The same model that is low-risk as an internal intelligence summary is high-risk when its draft text becomes a filed submission section. Misclassify here and everything downstream is mis-sized. This is a risk-management decision, so it inherits quality risk management under ICH Q9(R1).

WHAT. A documented classification of each AI use, by where the output goes and who is accountable for the consequence.

HOW. For each use, write one sentence naming the AI output, what it feeds, and the named human who owns the result. Then assign a tier:

The fourth tier is on the table only to rule it out. For regulatory and CMC content, there is no acceptable pattern where AI-generated text becomes filed content without a qualified human authoring and owning it.

Acceptance criteria. Every AI use in the regulatory and CMC workflow has a written classification, a named accountable role, and a sentence describing where its output goes. No use sits in the direct-to-record tier.

Common mistakes. Treating “AI for regulatory writing” as one undifferentiated tool rather than classifying each use. Letting an assistive-draft tool quietly drift into direct-to-record because the human review became a rubber stamp.

Interview angle. “How would you govern AI in regulatory writing?” Start by refusing to answer in general: it depends on whether the output is internal intelligence, an assistive draft, or a conformance check, and on where the output goes. The accountability and accuracy bar for filed content does not change, so the AI is always an assist with a named human owner.

2. Pin and control the AI system itself

WHY. You cannot defend output from a system you cannot describe. If the model can change under you, or you cannot say which version produced a given draft, you have no controlled process. This is the validation question, and it follows the validating AI-enabled GxP systems approach.

WHAT. A defined, version-controlled AI capability: the model or service, its version, the prompts and retrieval configuration, the guardrails, and the data it can see.

HOW.

• Where the AI is a vendor API (a large language model service), recognize that the base model is a black box you cannot inspect and the vendor can change it. Pin the model version where the vendor allows it, and put the vendor’s model-change behavior into your software supplier assessment.
• Treat the part you control, the prompts, the retrieval setup (which source documents the model is grounded in), the guardrails, and the output handling, as the configured artifact you validate and version.
• For drafting from internal data, ground the model in the actual source documents through retrieval rather than relying on its training, so the output is anchored to your real data and is checkable against it.
• Validate to the intended use and risk tier, not to a generic “the AI works” claim.

Acceptance criteria. For any AI-assisted regulatory output you can state which system and version produced it, what it was grounded in, and what guardrails applied. A vendor model change triggers a defined re-check before continued use.

Common mistakes. Using a general consumer AI tool with no version control or data governance for regulatory drafting. Accepting a vendor’s “validated for life sciences” claim as covering your specific configured use.

3. Ground every claim in a verifiable source

WHY. The characteristic failure of generative AI on regulatory content is the confident, fluent, wrong specific: a misstated specification limit, an invented citation, a transposed batch number, a fabricated study reference. This is often called confabulation or hallucination, and the danger is that it reads perfectly. The whole edifice of a submission rests on claims tracing to source records, so an unverifiable claim is not a small defect, it is the defect.

WHAT. A workflow in which every factual claim in AI-assisted content is traceable to a source document, and the traceability is checkable.

HOW.

• Use retrieval grounding: the model drafts from specific provided source documents, not from its general training, and it cites which source each statement came from.
• Require source citation in the draft itself, so the human reviewer can verify each claim against its named source rather than re-deriving it.
• Verify every regulatory citation against the primary source. Do not let the model assert a guidance number, a regulation identifier, or a date that has not been checked. If the model is unsure, it should say so rather than invent one.
• Treat numbers as high-risk tokens. Specification limits, results, dates, identifiers, and statistics get verified against source individually, not skimmed in context.

Acceptance criteria. Every factual claim in AI-assisted regulatory content can be traced to a verified source. No regulatory citation appears that has not been checked against the primary reference. Numeric values are confirmed against source records.

Common mistakes. Accepting fluent prose as accurate because it reads well. Letting a fabricated or mis-numbered citation through because no one checked it against the source. This is a straight ALCOA+ failure, the “accurate” and “original” attributes, wearing an AI costume.

Interview angle. “What is your single biggest worry with AI drafting a submission?” The confident wrong specific: a misstated number or invented citation in fluent text that no one catches. The mitigation is retrieval grounding, mandatory source citation in the draft, and individual verification of every number and reference against the primary source.

4. Make human authorship and accountability explicit

WHY. Regulatory content carries a human accountable for its truth. AI does not change who is accountable; it changes how the content was produced. The GxP principle that quality and regulatory decisions require documented human judgment is the foundation under 21 CFR Part 11 and the electronic signature it governs. A signature on a submission means a person stands behind the content, AI-assisted or not.

WHAT. A defined, recorded human authoring and approval step for any AI-assisted content that becomes regulatory output, with the reviewer’s accountability clear.

HOW.

• Name the author who takes ownership of AI-assisted content. The author is the accountable party, not the AI.
• Make the review meaningful, not a rubber stamp. The reviewer verifies claims against source, checks numbers and citations, and applies regulatory judgment to the framing. A model that is usually right breeds automation bias, where reviewers approve without truly checking, precisely because it is usually right. Design the workflow to resist that: present sources alongside claims, require the reviewer to confirm the high-risk specifics.
• Record the review in the controlled document workflow under document control, so there is evidence a qualified human authored and approved the final content.
• Train authors and reviewers on the AI’s known failure modes, so they review with the right suspicion.

Acceptance criteria. Every piece of AI-assisted regulatory output has a named human author who owns it, a recorded review that verified the substance, and approval through the controlled workflow. Reviewers are trained on AI failure modes.

Common mistakes. Treating the AI as the author and the human as a formality. A near-100 percent acceptance rate of AI drafts with no edits, which signals the review is not real. No training, so reviewers do not know to distrust fluent numbers.

5. Preserve the traceability and data integrity of the assisted content

WHY. A regulatory submission is a data-integrity artifact end to end. Adding an AI step adds a transformation, and every transformation is a place meaning can be lost or altered. The data lifecycle and metadata expectations apply to the assisted content, not just to the original source.

WHAT. A record of how AI-assisted content was produced, sufficient to reconstruct and defend it, and preservation of the source-to-submission chain.

HOW.

• Retain, for content that becomes regulatory output, a record of the AI’s involvement: which system and version, what sources it was grounded in, and the human authoring and review that followed. The detail scales with risk, more for a filed submission section, less for an internal intelligence summary.
• Keep the source-to-claim traceability intact through the AI step, so the final claim still traces to the original record.
• Apply the same good documentation practices to the assisted content as to any other: contemporaneous records of review, attributable approvals, controlled versions.
• Manage retention and access of the AI workflow records as GxP records where the output is regulatory content.

Acceptance criteria. For filed AI-assisted content, the record shows how it was produced and who owns it, and every claim still traces to a verified source. The assisted content lives in the controlled document system, not in an ungoverned AI tool’s history.

Common mistakes. No record of AI involvement, so when a question arises later about how a section was produced, there is nothing to show. Drafts and source links living only in a consumer AI tool’s chat history, outside any controlled system.

6. Govern change, in the product and in the AI

WHY. Two kinds of change have to be controlled. Changes to the product or its filing (labeling updates, variations, supplements) are classic regulatory change management. Changes to the AI system (a vendor model update, a prompt change, a new data source) can silently alter the behavior you validated. Both run through change control for validated systems, and the labeling change is especially sensitive.

WHAT. Change control covering both the regulatory content and the AI capability that helped produce it.

HOW.

• For labeling and filing changes, the AI assists the comparison and drafting, but the change goes through controlled change management with qualified approval. A labeling change never reaches a label on AI output alone.
• For the AI system, classify anticipated changes in advance, the predetermined change control idea, and define what each class requires. A vendor base-model update is a change you did not initiate: re-check the output quality on a known set before continuing to rely on it.
• Re-verify that AI behavior still meets the bar after any material change to the model, prompts, retrieval sources, or guardrails.

A change-classification table makes this operational:

Acceptance criteria. Labeling and filing changes go through controlled change management with human approval regardless of AI assistance. AI system changes are classified and trigger a defined re-verification.

Common mistakes. A vendor model change passing unnoticed, so the validated behavior lapses silently. Treating an AI-assisted labeling redline as authoritative without controlled review.

7. Monitor and review the assisted process

WHY. A process that was sound at launch can degrade: the vendor model drifts, the source data shifts, reviewers grow complacent. Without monitoring you have no evidence the AI assistance is still producing sound content. This is the regulatory-content analogue of the periodic review in the validation master plan and periodic review.

WHAT. Ongoing checks that AI-assisted regulatory content is still accurate and that the human controls are still working.

HOW.

• Track the rate and nature of corrections reviewers make to AI drafts. A rising error rate, or a shift in the kind of error, is a leading signal that the model behavior has changed. A near-zero edit rate is the opposite warning, that review has gone slack.
• Periodically audit a sample of AI-assisted content against source to confirm accuracy and traceability held up.
• Capture and review any case where an AI-introduced error reached a late stage or a submission, as a quality event with root cause and corrective action.
• Feed findings back into the prompts, the guardrails, and the reviewer training.

Acceptance criteria. Correction rates are tracked, a periodic accuracy audit runs, AI-error escapes are investigated as quality events, and findings drive improvement.

Common mistakes. Deploy and forget: no monitoring, so the first sign of trouble is an error in a filed document. Treating an AI-introduced error as a one-off rather than investigating the process that let it through.

A Worked Governance Example

Make it concrete. A regulatory affairs group wants to use an AI capability to draft first-pass nonclinical written summaries for the common technical document from a set of completed study reports. Here is the governance, end to end.

Classification. The use is assistive draft. The output, a draft summary section, will become filed content after a qualified regulatory writer authors and owns it. Named accountable role: the lead regulatory writer for the program. The use is documented with the sentence: “The AI produces a first-pass draft of the nonclinical written summary from the provided study reports; the regulatory writer verifies every claim against the source reports, edits, and owns the final section; QA approves through the document workflow.”

The system. A vendor language-model service, version pinned where the vendor allows. The model is grounded through retrieval in the specific study reports for this program, not its general training. A guardrail requires the draft to cite, for each statement, the source report and page it came from. The vendor’s model-change policy is captured in the supplier assessment. The configured use, prompts, retrieval set, guardrails, is validated to its assistive-draft risk tier.

Grounding and accuracy. The draft arrives with inline source citations. The writer verifies every numeric value (study results, doses, durations, identifiers) against the cited source report individually. Any regulatory citation in the draft is checked against the primary reference. Where the model flagged uncertainty rather than asserting a number, the writer supplies the verified value from source.

Human authorship. The regulatory writer is the named author. The review is substantive, not cosmetic: claim-by-claim verification against source, judgment on framing and emphasis, correction of anything the model got wrong. The writer is trained on the model’s known failure modes, including its tendency to produce fluent but occasionally wrong specifics. QA approves the final section through the controlled document workflow, applying Part 11 electronic signature.

Traceability and records. The final section traces every claim to a source study report. The controlled document record notes the AI assistance, the system version, and the human authoring and review. The drafts and source links live in the controlled document system, not in the AI tool’s chat history.

Change control. When the vendor announces a model update, the team treats it as an uninitiated change: it re-runs a known set of study reports through the drafting step and confirms the output quality before relying on the updated model. A change to the drafting prompt triggers a re-verification on representative content.

Monitoring. The team tracks the volume and type of corrections writers make to AI drafts across programs. A quarterly audit samples finished AI-assisted sections and re-checks a set of claims against source. Any case where an AI-introduced error reached late-stage review is logged and investigated under the deviation process, with corrective action fed back into the prompts and the training.

The result is a faster drafting process that an inspector or sponsor auditor can follow from source data to filed claim, with a named human accountable at every step and the AI clearly in an assistive role.

Roles and Responsibilities

AI in regulatory content fails most often at the seams between functions, because the AI capability, the content, and the quality oversight tend to sit in different groups. Name owners explicitly. Adapt titles to your organization.

The recurring failure is treating the AI capability as an IT tool that regulatory simply uses, with quality involved only at final approval. The accuracy and traceability controls, the grounding requirements, the validation, the change plan, need quality and regulatory involvement while the capability is being set up, not after the first error. See GxP roles and responsibilities for the broader model.

Common Inspection and Audit Findings

These are the failure patterns an inspector or sponsor auditor would surface, framed generically. Each maps to a real category of finding against documentation, data integrity, or computerized systems.

• Unverifiable claim in submitted content. A statement in a filed document that does not trace to a source, or traces to a source that does not support it. The classic AI-introduced version is a fluent but wrong specific that no one checked. A straight accuracy and traceability finding.
• Fabricated or wrong citation. A regulatory reference, guidance number, or study identifier that is invented or mis-numbered, produced by the model and not verified against the primary source.
• No record of how content was produced. AI was used in producing a submission section, but there is no record of the system, version, sources, or human authoring, so the process cannot be reconstructed when questioned.
• AI tool outside the controlled environment. Regulatory drafts and source links living in a consumer AI tool’s chat history rather than in the controlled document system, with no governance over access, retention, or the data fed in.
• Rubber-stamp authorship. A named author who in practice approved AI drafts unchanged, revealed by a near-zero edit rate, so the human accountability is nominal only.
• Vendor model change not controlled. The AI vendor updated the underlying model and the behavior changed, with no re-verification, so the validated state lapsed silently.
• Labeling driven by AI output. A labeling change made on an AI-generated redline without controlled change management and qualified review.
• No monitoring. No tracking of correction rates or periodic audit, so the first evidence of a problem is an error reaching a submission.
• Uncontrolled data into the model. Feeding source documents into an AI service without governing what data goes where, an access-control and data-governance gap that intersects with CSV cybersecurity and access control.

Interview Questions and How to Answer Them

If you are interviewing for a regulatory affairs, regulatory operations, or digital quality role and AI comes up, these are the questions that separate a practitioner from someone reciting features. Concrete answers win.

“Where would you use AI in regulatory affairs, and where would you not?” Use it for first-pass drafting from source data, summarizing long source documents, cross-document consistency checks, and regulatory intelligence on public databases. Do not let AI output become filed content without a qualified human authoring and owning it, and never drive a labeling change on AI output alone. The accuracy and accountability bar for filed content does not change because AI helped.

“How do you keep AI-assisted submission content accurate?” Ground the model in the actual source documents through retrieval rather than its training, require it to cite the source for each claim, and verify every number and every regulatory citation against the primary source individually. Fluent prose is not evidence of accuracy. A named human author owns the final content and is trained on the model’s failure modes.

“Who is accountable for a submission section an AI helped draft?” The named human author and the approver, exactly as before AI. The AI is an assist. The signature on the content means a qualified person stands behind it, and that does not transfer to a model.

“How would you handle the vendor updating their model under you?” Treat it as a change I did not initiate. Pin the version where the vendor allows it, capture the vendor’s change behavior in the supplier assessment, and when an update lands, re-run a known set of content through the workflow and confirm output quality before relying on the updated model.

“An AI-introduced error made it into a draft submission and was caught at final review. What do you do?” Log it as a quality event, find the root cause (was it a grounding gap, a missed verification step, slack review), and put corrective action in: fix the prompt or guardrail, reinforce the verification step, retrain the reviewer if needed. Then check whether the same error pattern exists elsewhere. A single escape is a signal about the process, not a one-off.

“What records would an inspector expect for AI-assisted regulatory content?” That the content traces every claim to a verified source, that a named human authored and approved it through the controlled document workflow, and, scaled to risk, a record of the AI’s involvement, which system and version and what it was grounded in. Enough to reconstruct and defend how the content was produced.

“How do the FDA’s 2025 draft AI guidance and the EU draft Annex 22 apply here?” Both are drafts, so direction of travel rather than binding law. The FDA draft proposes a seven-step, risk-based credibility assessment for AI models whose output supports a regulatory decision, which is the same classify-then-size logic I use, though its target is narrower than a writing assist: it fits best where a model’s output feeds a submission claim directly. The draft Annex 22 limits generative AI to non-critical uses with documented human oversight, which is exactly where regulatory drafting sits and matches the assist-with-a-human-owner stance I take anyway. I keep building to Part 11, Annex 11, and ICH Q9(R1), and confirm the published text before citing either draft.

The Practical Bottom Line

AI is a real productivity gain in regulatory affairs and CMC: it cuts blank-page time on drafting, makes long source documents tractable to summarize, catches cross-document inconsistencies humans miss, and speeds up scanning the public regulatory environment. None of that is in dispute.

What the productivity gain cannot buy is a reduction in accountability or accuracy. A regulatory submission is a representation to a health authority and a labeling statement is a patient-safety document, and the standard for those does not move because an AI helped produce them. The governance that keeps AI-assisted regulatory content defensible is not exotic: classify each use and name who owns the output, pin and control the AI system, ground every claim in a verifiable source, keep a qualified human as the accountable author, preserve the source-to-claim traceability and the records, control change in both the filing and the AI, and monitor the process so degradation surfaces before it reaches a submission.

Done that way, the AI sits clearly in an assistive role, the human accountability is intact, and the file reads to an inspector or a sponsor auditor as a process under control rather than a shortcut that quietly moved the accuracy risk somewhere no one is watching.